EZH2 and pancreatic neoplasm: Herein, we show that HAT1 knockdown in pancreatic cancer cells increases gemcitabine sensitivity and decreases PVT1/EZH2 complex levels, suggesting that HAT1 may represent a promising therapeutic target in pancreatic cancer.